Parexel acquires ClinIntel for trial supply services
pharmafile | October 6, 2014 | News story | Manufacturing and Production | CRO, Paraxel, clinical research organisation, clinintel, manufacturing
Clinical research organisation Parexel has acquired all of the outstanding equity securities of privately-owned ClinIntel, a UK-based provider of clinical randomisation and trial supply management services.
ClinIntel’s offerings will be combined into the firm’s ClinPhone clinical randomisation and trial supply management services (RTSM), suite and are designed to make patient randomisation and clinical supply chain solutions more efficient, according to Parexel.
Financial details of the deal were not disclosed but its capabilities include advanced RTSM technologies for planning, forecasting and supply chain eLogistics.
The offerings are also designed to help accelerate study start-up timelines. The entire ClinPhone RTSM suite will be available through the Perceptive MyTrials platform and as a standalone solution, and both solutions will be available through the Perceptive Partner Program [sic].
ClinIntel was founded in 2009, and works with biopharmaceutical companies and contract research organisations. The company is headquartered in Crawley, West Sussex and the acquisition was funded with existing cash.
The impact of the acquisition on Parexel’s fiscal year 2015 revenue and earnings per share is not expected to be material, and the business will be integrated into the company’s so-called Informatics segment.
Josef von Rickenbach, chairman and chief executive of Parexel International, says: “As the use of technology has expanded in the conduct of clinical research, Parexel has been a leader in RTSM.
“By combining the trial supply management technologies from ClinIntel with our existing ClinPhone solutions, we believe we have an opportunity to further advance our position as a clinical technology leader and grow market share by bringing enhanced speed, efficiency, and simplicity to our RTSM offering.”
Ben Adams
Related Content
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
AbbVie invests $223m in Singapore manufacturing site
AbbVie has announced that it has invested $223m in an expansion to its Singapore manufacturing …
